Regulatory approval

Published by the Health Canada. Approved

Health Canada approved brentuximab vedotin for the treatment of adult patients with CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.

This is written in the approval document as:

ADCETRIS is indicated for the treatment of adult patients with CD30-expressing MF who have received prio systemic therapy

Citation

Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	CD30 +	Mycosis Fungoides	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals